STEWARTVILLE, Minn.,
Oct. 10, 2013 /PRNewswire/
-- Rochester Medical Corporation (NASDAQ: ROCM), has
established a record date and a special meeting date for the
Company's shareholders to consider and vote on the proposal to
adopt the previously announced agreement to be acquired by a
subsidiary of C.R. Bard, Inc. On September
4, 2013, Rochester Medical announced that it had entered
into a definitive agreement to be acquired by a subsidiary of C.R.
Bard, Inc. for $20.00 in cash per
common share for a total transaction value of approximately
$262 million.
(Logo:
http://photos.prnewswire.com/prnh/20121228/CG34999LOGO)
Rochester Medical shareholders of record at the close of
business September 30, 2013 are
entitled to notice of the special meeting and to vote on the
adoption of the agreement. The special meeting is scheduled for
November 13, 2013 at 2:00 p.m. central time, at the offices of Dorsey
& Whitney LLP, 15th floor, 50 South Sixth Street, Minneapolis, Minn. 55402. The definitive proxy
statement for the special meeting will be filed with the Securities
and Exchange Commission and mailed to shareholders on or about
October 14, 2013.
About Rochester Medical
Rochester Medical Corporation develops, manufactures, and
markets disposable medical catheters and devices for urological and
continence care applications. The Company also sells certain
ostomy and wound and scar care products and other brands of
urological products into the European marketplace.
For further information, please contact Anthony J. Conway,
President and Chief Executive Officer or David A. Jonas, Chief Financial Officer
of Rochester Medical Corporation at (507) 533-9600 or
Mike Piccinino, at Westwicke
Partners (443) 213-0500. More information
about Rochester Medical is available on its website
at http://www.rocm.com.
Additional Information and Where to Find It
Rochester Medical Corporation ("Rochester Medical") plans to
file with the Securities and Exchange Commission (the "SEC") and
furnish to its shareholders a definitive proxy statement in
connection with the proposed merger with a wholly owned subsidiary
of C. R. Bard, Inc. (the "Merger"), pursuant to which
Rochester Medical would be acquired by C. R. Bard, Inc.
("Bard"). The proxy statement will contain important information
about the proposed merger and related matters. INVESTORS AND
SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT CAREFULLY WHEN
IT BECOMES AVAILABLE. Investors and shareholders will be able to
obtain free copies of the proxy statement (when they are available)
and other documents filed with the SEC by Rochester Medical through
the web site maintained by the SEC at www.sec.gov. In addition,
investors and shareholders will be able to obtain free copies of
the proxy statement from Rochester Medical by contacting investor
relations by telephone at +1 (507) 533-9600, by mail at Rochester
Medical Corporation, One Rochester Medical Drive, Stewartville, MN, 55976, Attn: Investor
Relations, or by going to Rochester Medical's Investor Relations
page on its corporate website at http://www.rocm.com.
Rochester Medical and its directors and executive officers may
be deemed to be participants in the solicitation of proxies from
the shareholders of Rochester Medical in connection with the
proposed merger. Information regarding the interests of these
directors and executive officers in the transaction described
herein will be included in the proxy statement described above.
Additional information regarding these directors and executive
officers is also included in Rochester Medical's proxy statement
for its 2013 Annual Meeting of Shareholders, which was filed with
the SEC on December 28, 2012. This document is available free
of charge at the SEC's web site at www.sec.gov, and from Rochester
Medical by contacting investor relations by telephone at +1 (507)
533-9600, by mail at Rochester Medical Corporation, One Rochester
Medical Drive, Stewartville, MN,
55976, Attn: Investor Relations, or by going to Rochester Medical's
Investor Relations page on its corporate website at
http://www.rocm.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to,
statements about the future financial and operating results of
Rochester Medical. Such statements are based on currently
available information, operating plans and management's
expectations about future events and trends. Such statements
inherently involve significant risks and uncertainties that could
cause actual results to differ materially from those predicted in
such forward-looking statements, including the uncertainty of
estimated revenues and profits, the uncertainty of current domestic
and international economic conditions that could adversely affect
the level of demand for the Company's products and increased
volatility in foreign exchange rates, the uncertainty of market
acceptance of new product introductions, and our level of
success in increasing Rochester Medical Direct Sales revenue,
the uncertainty of gaining new strategic relationships or locating
and capitalizing on strategic opportunities, the uncertainty of
timing of Private Label Sales revenues (particularly international
customers), FDA and other regulatory review and response
times, and other risk factors listed from time to time in the
Company's SEC reports and filings, including, without limitation,
the section entitled "Risk Factors" in the Company's Annual Report
on Form 10-K for the year ended September 30, 2012,
and quarterly reports on Forms 10-Q. Readers are cautioned
not to place undue reliance on any such forward-looking statements,
which speak only as of the date they are made. The Company
undertakes no obligation to update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
Rochester Medical
Investor Relations
507-533-9600
SOURCE Rochester Medical Corporation